Abstract
The mechanisms of lithium action are not known in detail. First messengers, second messengers, and gene expression all appear to be involved: the wide breadth of targets makes the lithium therapeutic path difficult to disentangle. In the present paper, we focused on the most direct biochemical lithium targets at therapeutic concentration, for which some pharmacogenetic finding is present (i.e. inositol mono phosphatase (IMPase), inositol polyphosphate-1-phosphatase (IPPase) and glycogen sinthase kinase 3 beta (GSK-3 beta)). They are all inhibited by lithium at therapeutic concentrations and are representative of the inositol depletion and of the GSK-3 beta based theories of lithium action. Then we surveyed gene variants on those targets that have been associated also with bipolar disorder. On the basis of the molecular characteristics of these proteins, we suggest a set of critical genetic variations. IMPase2, IPPase and GSK-3 beta gene appear to be good candidates for the analysis of lithium prophylactic efficacy and bipolar disorder phenotypes but the genetic association analysis conducted so far reported negative or not unequivocal finding. This may be due to the incomplete coverage of gene mutations in most studies or to the several actions that lithium is thought to perform and trigger in cell machinery, including receptors, calcium equilibrium, gene expression, activation of neuroprotective paths and other yet undetected or less considered mechanisms.
Keywords: Lithium, pharmacogenetics, candidate gene, bipolar disorder, psychopharmacology
Current Medicinal Chemistry
Title: Lithium Pharmacodynamics and Pharmacogenetics: Focus on Inositol Mono Phosphatase (IMPase), Inositol Poliphosphatase (IPPase) and Glycogen Sinthase Kinase 3 Beta (GSK-3 Beta)
Volume: 16 Issue: 15
Author(s): Alessandro Serretti, Antonio Drago and Diana De Ronchi
Affiliation:
Keywords: Lithium, pharmacogenetics, candidate gene, bipolar disorder, psychopharmacology
Abstract: The mechanisms of lithium action are not known in detail. First messengers, second messengers, and gene expression all appear to be involved: the wide breadth of targets makes the lithium therapeutic path difficult to disentangle. In the present paper, we focused on the most direct biochemical lithium targets at therapeutic concentration, for which some pharmacogenetic finding is present (i.e. inositol mono phosphatase (IMPase), inositol polyphosphate-1-phosphatase (IPPase) and glycogen sinthase kinase 3 beta (GSK-3 beta)). They are all inhibited by lithium at therapeutic concentrations and are representative of the inositol depletion and of the GSK-3 beta based theories of lithium action. Then we surveyed gene variants on those targets that have been associated also with bipolar disorder. On the basis of the molecular characteristics of these proteins, we suggest a set of critical genetic variations. IMPase2, IPPase and GSK-3 beta gene appear to be good candidates for the analysis of lithium prophylactic efficacy and bipolar disorder phenotypes but the genetic association analysis conducted so far reported negative or not unequivocal finding. This may be due to the incomplete coverage of gene mutations in most studies or to the several actions that lithium is thought to perform and trigger in cell machinery, including receptors, calcium equilibrium, gene expression, activation of neuroprotective paths and other yet undetected or less considered mechanisms.
Export Options
About this article
Cite this article as:
Serretti Alessandro, Drago Antonio and De Ronchi Diana, Lithium Pharmacodynamics and Pharmacogenetics: Focus on Inositol Mono Phosphatase (IMPase), Inositol Poliphosphatase (IPPase) and Glycogen Sinthase Kinase 3 Beta (GSK-3 Beta), Current Medicinal Chemistry 2009; 16 (15) . https://dx.doi.org/10.2174/092986709788186101
DOI https://dx.doi.org/10.2174/092986709788186101 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Lower Uric Acid Linked with Cognitive Dysfunction in the Elderly
CNS & Neurological Disorders - Drug Targets Current Advances on Different Kinases Involved in Tau Phosphorylation, and Implications in Alzheimers Disease and Tauopathies
Current Alzheimer Research Genetic Predisposition in NAFLD and NASH: Impact on Severity of Liver Disease and Response to Treatment
Current Pharmaceutical Design Alterations in Glucose Metabolism in Alzheimer's Disease
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Improved Hepatic Differentiation Strategies for Human Induced Pluripotent Stem Cells
Current Molecular Medicine Cell-Penetrating Peptide-Mediated Topical Delivery of Biomacromolecular Drugs
Current Pharmaceutical Biotechnology Towards Second Generation Hypericin Based Photosensitizers for Photodynamic Therapy
Current Organic Chemistry Docking of Natural Products against Neurodegenerative Diseases: General Concepts
Combinatorial Chemistry & High Throughput Screening Apathy: A Conceptual Review
Current Psychiatry Research and Reviews Hemopressin Peptides as Modulators of the Endocannabinoid System and their Potential Applications as Therapeutic Tools
Protein & Peptide Letters Potential Application of Biliverdin Reductase and its Fragments to Modulate insulin/IGF-1/MAPK/PI3-K Signaling Pathways in Therapeutic Settings
Current Drug Targets Current Pharmaceutical Aspects of Synthetic Quinoline Derivatives
Mini-Reviews in Medicinal Chemistry Cytochrome P450-Activated Prodrugs: Targeted Drug Delivery
Current Medicinal Chemistry An Overview of Computer-aided Drug Design Tools and Recent Applications in Designing of Anti-diabetic Agents
Current Drug Targets PET and SPECT Radiotracers for Alzheimer's Disease
Current Medicinal Chemistry The Role of P-Glycoprotein in Psychiatric Disorders: A Reliable Guard of the Brain?
Central Nervous System Agents in Medicinal Chemistry The Effect of Pyrroloquinoline Quinone on Apoptosis and Autophagy in Traumatic Brain Injury
CNS & Neurological Disorders - Drug Targets Clinical Application of Sorafenib for Treating Hepatocellular Carcinoma and Beyond
Clinical Cancer Drugs Hypersensitivity Reactions from Excipients in Systemic Glucocorticoid Formulations
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Peripartum Cardiomyopathy: Current State of Knowledge, New Developments and Future Directions
Current Cardiology Reviews